Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Purchased by Penobscot Investment Management Company Inc.

Penobscot Investment Management Company Inc. grew its stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,450 shares of the company’s stock after purchasing an additional 450 shares during the quarter. Penobscot Investment Management Company Inc.’s holdings in Invesco Biotechnology & Genome ETF were worth $1,294,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of PBE. Millstone Evans Group LLC purchased a new position in shares of Invesco Biotechnology & Genome ETF in the fourth quarter valued at $64,000. Jones Financial Companies Lllp boosted its position in Invesco Biotechnology & Genome ETF by 52.9% in the 4th quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock valued at $154,000 after buying an additional 801 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the fourth quarter valued at about $161,000. Jane Street Group LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter worth about $295,000. Finally, HighTower Advisors LLC lifted its stake in shares of Invesco Biotechnology & Genome ETF by 64.1% in the third quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock worth $494,000 after acquiring an additional 2,774 shares in the last quarter.

Invesco Biotechnology & Genome ETF Stock Down 2.1 %

Shares of NYSEARCA PBE opened at $64.89 on Thursday. Invesco Biotechnology & Genome ETF has a fifty-two week low of $59.32 and a fifty-two week high of $72.84. The business has a 50 day moving average price of $67.36 and a two-hundred day moving average price of $68.46. The firm has a market cap of $235.55 million, a PE ratio of 23.00 and a beta of 0.80.

Invesco Biotechnology & Genome ETF Increases Dividend

The business also recently declared a dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 24th will be given a dividend of $0.0341 per share. The ex-dividend date of this dividend is Monday, March 24th. This is an increase from Invesco Biotechnology & Genome ETF’s previous dividend of $0.01.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.